HONG KONG – Generon Corp. (Shanghai) Ltd. has reached an agreement with the FDA under a special protocol assessment (SPA) regarding the second pivotal global phase III study design of its chemotherapy-induced neutropenia (CIN) treatment.
HONG KONG – YL Biologics Ltd. has inked a licensing deal to distribute a biosimilar for the treatment of anemia by Korea’s CJ Healthcare Ltd. in Japan. The drug, CJ-40001, is CJ Healthcare’s version of Amgen Inc.’s Aranesp (darbepoetin alfa).
HONG KONG – Chinese biotech company Hybio Pharmaceutical Co. recently received approval from the CFDA to conduct clinical trials for its generic version of GLP-1 analogue liraglutide.
HONG KONG Abbvie Inc. has added a biologics manufacturing unit in its Singapore plant, to ensure sufficient supply of biomedicines and perfect the ecosystem of biologics innovation in the region.
HONG KONG Abbvie Inc. has added a biologics manufacturing unit in its Singapore plant, to ensure sufficient supply of biomedicines and perfect the ecosystem of biologics innovation in the region.
HONG KONG Amgen Inc. and Simcere Pharmaceutical Group have entered into an agreement to develop and commercialize four biosimilars for the Chinese market.
